Related Experiment Video

Updated: Jun 13, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Clinical overview of sorafenib in breast cancer

Alvaro Moreno-Aspitia1

  • 1Mayo College of Medicine, Multidisciplinary Breast Clinic, Mayo Clinic Florida, FL, USA. morenoaspitia.alvaro@mayo.edu

Future Oncology (London, England)
|May 15, 2010
PubMed

Insights

Sorafenib, a multikinase inhibitor, targets key pathways in metastatic breast cancer. This review examines its role in combating cancer cell proliferation and tumor growth, offering insights into treatment strategies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Breast carcinoma is a leading cause of cancer-related deaths in women globally.
  • Despite advances, metastatic breast cancer recurrence remains a significant clinical challenge.
  • Targeting aberrant cell signaling pathways is crucial for novel breast cancer therapies.

Purpose of the Study:

  • To review the therapeutic potential of sorafenib in breast cancer.
  • To discuss the mechanisms of action of sorafenib against cancer pathways.
  • To explore current and future strategies for sorafenib in breast cancer treatment.

Main Methods:

  • Review of existing literature on sorafenib in breast cancer.
  • Analysis of sorafenib's inhibitory effects on receptor tyrosine kinases.
  • Examination of its impact on Ras/Raf/MAPK/ERK and VEGF pathways.

Main Results:

  • Sorafenib demonstrates multikinase inhibitory activity against critical cancer pathways.
  • It interferes with receptor tyrosine kinases implicated in breast cancer progression.
  • The drug shows potential in inhibiting tumor growth, proliferation, invasion, and neo-angiogenesis.

Conclusions:

  • Sorafenib represents a promising targeted therapy for metastatic breast cancer.
  • Further research and clinical development are warranted to optimize its use.
  • Understanding its role in key signaling cascades can guide future treatment strategies.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...